IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
Rhea-AI Summary
IceCure Medical (Nasdaq: ICCM) will report financial and operating results for the three months ended March 31, 2026 on Tuesday, May 12, 2026 before the Nasdaq opens. A conference call and live webcast to discuss results and corporate developments will be held at 11:00 a.m. EDT the same day.
Investors may join by phone (US: 1-888-407-2553; Israel/International: +972-3-918-0696) or via webcast at the company webcast link; a recording will be posted on the investor site.
Positive
- None.
Negative
- None.
News Market Reaction – ICCM
In the May 6 session, ICCM declined 6.57%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.5% during that session. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Earnings date announcement | Neutral | +0.3% | Announcement of date and call details for 2025 full year results. |
| Nov 12 | Earnings date announcement | Neutral | +2.5% | Scheduling Q3 2025 results release and investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past earnings date announcements for ICCM have been followed by modest positive price moves averaging 1.37%, indicating generally muted but slightly constructive reactions to scheduling communications.
Over recent months, IceCure has combined operational progress with capital markets activity. Record 2025 revenue of $3.379M and a narrowed net loss of $15.057M were followed by a $4.0M registered direct offering and concurrent warrants. Clinical updates and growing U.S. ProSense® adoption, including >30% U.S. revenue growth indications, have not yet translated into sustained price strength. Today’s Q1 2026 earnings date notice continues the pattern of scheduled result disclosures with accompanying conference calls.
Key Terms
cryoablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call & webcast info:
Tuesday, May 12, 2026, at 11:00 am EDT
US: 1-888-407-2553
A live webcast will be available at: https://www.veidan-conferencing.com/icecure-investors
A recording of the webcast will be available at: ir.icecure-medical.com
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the timing for announcing its financial and operating results for the three month ended March 31, 2026 and the related conference call. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-first-quarter-2026-financial-and-operating-results-on-may-12-2026-302764075.html
SOURCE IceCure Medical